Phio Pharmaceuticals stock drops 39.1% after announcing a $3.19 million direct offering and concurrent private placement.

Greenwich LifeSciences (GLSI), focused on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast ...

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

According to ACS, chemotherapy may be given after surgery (adjuvant), when it may help destroy traces of cancer, or before ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...